UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trade Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events.
On June 21, 2023, AlloVir, Inc. (“AlloVir”) notified SVB Securities LLC (“SVB”) that it was suspending its use of and terminating the prospectus supplement (the “ATM Prospectus Supplement”), related to the potential issuance from time to time of AlloVir’s common stock pursuant to the Sales Agreement, dated August 6, 2021, by and between AlloVir and SVB (the “Sales Agreement”). AlloVir will not make any sales of its securities pursuant to the Sales Agreement, unless and until a new prospectus supplement or a new registration statement is filed. Other than the termination of the ATM Prospectus Supplement, the Sales Agreement remains in full force and effect.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AlloVir, Inc. | ||||||
| Date: June 21, 2023 | By: | /s/ William Wheeler | ||||
| Name: | William Wheeler | |||||
| Title: | Senior Vice President, Corporate Law | |||||
Document and Entity Information |
Jun. 21, 2023 |
|---|---|
| Cover [Abstract] | |
| Entity Address, State or Province | MA |
| Amendment Flag | false |
| Entity Central Index Key | 0001754068 |
| Document Type | 8-K |
| Document Period End Date | Jun. 21, 2023 |
| Entity Registrant Name | ALLOVIR, INC. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-39409 |
| Entity Tax Identification Number | 83-1971007 |
| Entity Address, Address Line One | AlloVir, Inc. |
| Entity Address, Address Line Two | 1100 Winter Street |
| Entity Address, City or Town | Waltham |
| Entity Address, Postal Zip Code | 02451 |
| City Area Code | (617) |
| Local Phone Number | 433-2605 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, $0.0001 par value per share |
| Trading Symbol | ALVR |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |